References
- Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol 2002;59:1937-43
- Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6
- Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, non-motor outcomes. Lancet Neurol 2011;10:415-23
- Lew MF, Hauser RA, Hurtig HI, et al. Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci 2010;120:404-8
- Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53
- Grosset KA, Grosset DG. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. Mov Disord 2005;20:616-19
- Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-17
- Tarrants ML, Denarie MF, Castelli-Haley J, et al. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 2010;8:374-83
- Le Parc JM, Van Ganse E, Moore N, et al. Comparative tolerability of paracetamol, aspirin and ibuprofen for short-term analgesia in patients with musculoskeletal conditions: results in 4291 patients. Clin Rheumatol 2002;21:28-31
- Azilect (rasagiline) Summary of Product Characteristics. November 2010
- Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78
- Chou KL. Adverse events from the treatment of Parkinson's disease. Neurol Clin 2008;26(3 Suppl):S65-83, vi
- Thornton C, Dore CJ, Elsworth JD, et al. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology (Berl) 1980;70:163-6
- Lecht S, Haroutiunian S, Hoffman A, et al. Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag 2007;3:467-74
- Gescheidt T, Bares M. Impulse control disorders in patients with Parkinson's disease. Acta Neurol Belg 2011;111:3-9
- Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010;16:202-7